Trial Profile
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2021
Price :
$35
*
At a glance
- Drugs Transcrocetinate sodium (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms INTACT
- Sponsors Diffusion Pharmaceuticals
- 01 Jul 2021 Status changed from completed to discontinued.
- 07 Jan 2021 Status changed from suspended to completed.
- 10 Aug 2020 According to a Diffusion Pharmaceuticals media release, the company has successful completed the 19-patient open-label, dose-escalation lead-in safety portion of the trial.